Amplifon’s $2 billion move into manufacturing: what it means for audiology

From our audiology editor Yovina Khiroya
Amplifon, the world’s largest hearing aid retailer, has announced a reported $2 billion acquisition of GN Hearing, the company behind ReSound, Beltone and Jabra Enhance. While headline-grabbing, the strategic implications are arguably more significant than the deal value itself.

Historically, Amplifon has operated as a retail-led organisation, relying on major manufacturers such as Sonova, Demant and GN for product supply. This acquisition signals a clear shift from distributor to fully vertically integrated provider, spanning research and development, manufacturing, and clinical delivery.

Vertical integration is not new in healthcare, but within audiology it represents a notable evolution. By bringing manufacturing in-house, Amplifon gains greater control over product development cycles, pricing structures, and potentially the patient journey. This could enable faster innovation and more streamlined care pathways, particularly in markets where Amplifon maintains a strong retail presence.

The move is also somewhat unexpected. Previous industry speculation had centred around a potential merger between GN and Demant, a more traditional consolidation of manufacturing entities. Instead, this transaction reflects a broader trend seen across healthcare, namely the convergence of retail and production.

For patients, the impact may be positive in terms of innovation and service integration. However, for the wider profession, the implications are more complex. The deal further widens the gap between large corporate providers and independent clinics, raising questions around competition, supplier relationships, and long-term market dynamics.

In the UK, the immediate effects may be limited following Amplifon’s recent market exit. Globally, however, this acquisition is likely to reshape competitive structures and accelerate the shift towards vertically integrated audiology models.